USA - NASDAQ:BTMD - US0906831039 - Common Stock
The current stock price of BTMD is 2.89 USD. In the past month the price decreased by -3.34%. In the past year, price decreased by -43.66%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.11 | 781.26B | ||
| JNJ | JOHNSON & JOHNSON | 18.34 | 458.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.76 | 258.24B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.73 | 252.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.65 | 235.32B | ||
| MRK | MERCK & CO. INC. | 11.36 | 218.53B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 14.34 | 125.85B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.51 | 89.21B | ||
| GSK | GSK PLC-SPON ADR | 9.67 | 86.97B | ||
| ZTS | ZOETIS INC | 23.46 | 64.68B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.04 | 44.25B |
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 217 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
BIOTE CORP -A
1875 W. Walnut Hill Ln #100, Floor 5
Irving TEXAS US
Employees: 217
Phone: 19724869346
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 217 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
The current stock price of BTMD is 2.89 USD. The price decreased by -1.7% in the last trading session.
BTMD does not pay a dividend.
BTMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
BTMD stock is listed on the Nasdaq exchange.
The PE ratio for BIOTE CORP -A (BTMD) is 2.95. This is based on the reported non-GAAP earnings per share of 0.98 and the current share price of 2.89 USD.
The outstanding short interest for BIOTE CORP -A (BTMD) is 3.22% of its float.
ChartMill assigns a fundamental rating of 5 / 10 to BTMD. BTMD has only an average score on both its financial health and profitability.
Over the last trailing twelve months BTMD reported a non-GAAP Earnings per Share(EPS) of 0.98. The EPS increased by 366.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.73% | ||
| ROA | 29.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
12 analysts have analysed BTMD and the average price target is 5.51 USD. This implies a price increase of 90.7% is expected in the next year compared to the current price of 2.89.
For the next year, analysts expect an EPS growth of 166.59% and a revenue growth -2.93% for BTMD